Merck And Co Inc patents expiration
1. Emend patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214692 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Sep, 2012
(11 years ago) | |
| US5538982 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Jul, 2013
(10 years ago) | |
| US5512570 | MERCK AND CO INC | Treatment of emesis with morpholine tachykinin receptor antagonists |
Mar, 2014
(10 years ago) | |
| US5716942 | MERCK AND CO INC | Treatment of migraine with morpholine tachykinin receptor antagonists |
Feb, 2015
(9 years ago) | |
| US5691336 | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Mar, 2019
(5 years ago) | |
|
US5691336 (Pediatric) | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Sep, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-186) | May 02, 2025 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| New Patient Population(NPP) | Apr 03, 2021 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient
NCE-1 date: 03 October, 2020
Market Authorisation Date: 25 January, 2008
Treatment: Prevention or treatment of nausea or emesis induced by a cancer chemotherapeutic agent
Dosage: POWDER;INTRAVENOUS
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
